search
Back to results

Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection

Primary Purpose

Macular Degeneration

Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Proparacaine Ophthalmic
Tetracaine Ophthalmic
Lidocaine 4%
Lidocaine 2% Injectable Solution
Sponsored by
Lahey Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Macular Degeneration focused on measuring Macular Degeneration, Intravitreal injections, Eye anesthesia-Topical/subconjunctival, Eye-surgical procedures, Ophthalmologic anesthesia methods

Eligibility Criteria

40 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female > 40 years of age
  • Diagnosis of age-related macular degeneration
  • History of at least 1 intravitreal injection in the past in either eye
  • Written informed consent has been obtained

Exclusion Criteria:

  • Known allergy or sensitivity to the study medications(s), it's components, or other agents required for the study procedures(e.g. Povidone iodine)

Sites / Locations

  • Lahey Clinic Arlington
  • Lahey Clinic, Inc.
  • Lahey Clinic Northshore

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

All Participants

Arm Description

All Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparacaine Ophthalmic drops used prior to Injection 1; Tetracaine Ophthalmic drops used prior to Injection 2; Lidocaine 4% sponge used prior to Injection 3; Lidocaine 2% injectable solution (subconjunctival) used prior to Injection 4).

Outcomes

Primary Outcome Measures

Discomfort Associated With the Intravitreal Injection
Discomfort Associated With the Intravitreal Injection using a Subjective Analog Pain Scale (0-10); no pain (0) and severe pain (10)

Secondary Outcome Measures

Discomfort From Anesthesia Used Prior to Intravitreal Injections
Discomfort from Anesthesia used prior to Intravitreal Injections using a Subjective Analog Pain Scale (0-10); no pain (0) and severe pain (10).

Full Information

First Posted
October 8, 2008
Last Updated
February 21, 2020
Sponsor
Lahey Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT00769392
Brief Title
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
Official Title
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Completed
Study Start Date
September 2008 (undefined)
Primary Completion Date
August 12, 2009 (Actual)
Study Completion Date
August 12, 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lahey Clinic

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study is designed to compare four currently used types of anesthesia used prior to intravitreal injection in order to evaluate the most effective method of anesthesia in reducing pain and discomfort associated with intravitreal injections.
Detailed Description
Over the last several years intravitreal injection of pharmacologic agents has become a common procedure in ophthalmology. Injected agents include steroid, antibiotics, and most recently anti-VEGF agents. There are many methods of preparing a patient for intravitreal injection. While there are guidelines for infection prophylaxis, there is currently no standard of care or consensus on which method of anesthesia is most effective in reducing pain and discomfort associated with intravitreal injections. Patients who have received prior injections and are scheduled to continue regular injections will be randomized to utilize one of four types of anesthetic treatment for each of 4 treatment periods,so that each subject receives all four types of anesthesia over the course of the study. The order of the anesthetic treatment the subject will receive prior to each planned intravitreal injection during the study period will be different for each subject. This will decrease the effect of extraneous variables from influencing subjective pain scores. Following each procedure, patients will fill out an analog pain scale questionnaire, grading the discomfort of receiving both the anesthesia and the injection(on separate 0-10 scales). The anesthetic methods used will include: 1.) Drops of Proparacaine on the eye, 2.) Drops of Tetracaine on the eye, 3.) A cotton sponge (pledget) soaked with Lidocaine 4% placed over the conjunctiva and 4.)A subconjunctival injection with 2% Lidocaine. The subjects' number and type of visits, tests and treatments will be standard of care and will not be different due to the study. The total time for the treatment part of the study coincides with four injections (1 injection per month) or approximately 4 months and will be followed for up to 6 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Macular Degeneration
Keywords
Macular Degeneration, Intravitreal injections, Eye anesthesia-Topical/subconjunctival, Eye-surgical procedures, Ophthalmologic anesthesia methods

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparcacaine used prior to Injection 1; Tetracaine used prior to Injection 2; Lidocaine sponge used prior to Injection 3; Lidocaine suconjunctival injection used prior to Injection 4).
Masking
None (Open Label)
Enrollment
28 (Actual)

8. Arms, Groups, and Interventions

Arm Title
All Participants
Arm Type
Other
Arm Description
All Participants will be randomized to receive a unique sequence of one of the 4 anesthetic agents per month, prior to a standard of care monthly intravitreal injection (1 injection per month for a total of 4 months). At the end of study participation, each patient will have received each of the 4 anesthetic agents once prior to one of the 4 intravitreal injections (ex. Randomization to sequence: Proparacaine Ophthalmic drops used prior to Injection 1; Tetracaine Ophthalmic drops used prior to Injection 2; Lidocaine 4% sponge used prior to Injection 3; Lidocaine 2% injectable solution (subconjunctival) used prior to Injection 4).
Intervention Type
Drug
Intervention Name(s)
Proparacaine Ophthalmic
Intervention Description
Drops of Proparacaine on the eye, administered as described in the package insert
Intervention Type
Drug
Intervention Name(s)
Tetracaine Ophthalmic
Intervention Description
Drops of Tetracaine on the eye, administered as described in the package insert
Intervention Type
Drug
Intervention Name(s)
Lidocaine 4%
Intervention Description
A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
Intervention Type
Drug
Intervention Name(s)
Lidocaine 2% Injectable Solution
Intervention Description
A subconjunctival injection of Lidocaine 2%
Primary Outcome Measure Information:
Title
Discomfort Associated With the Intravitreal Injection
Description
Discomfort Associated With the Intravitreal Injection using a Subjective Analog Pain Scale (0-10); no pain (0) and severe pain (10)
Time Frame
16 weeks
Secondary Outcome Measure Information:
Title
Discomfort From Anesthesia Used Prior to Intravitreal Injections
Description
Discomfort from Anesthesia used prior to Intravitreal Injections using a Subjective Analog Pain Scale (0-10); no pain (0) and severe pain (10).
Time Frame
16 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female > 40 years of age Diagnosis of age-related macular degeneration History of at least 1 intravitreal injection in the past in either eye Written informed consent has been obtained Exclusion Criteria: Known allergy or sensitivity to the study medications(s), it's components, or other agents required for the study procedures(e.g. Povidone iodine)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gregory R. Blaha, M.D., Ph.D.
Organizational Affiliation
Lahey Clinic, Inc.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Lahey Clinic Arlington
City
Arlington
State/Province
Massachusetts
ZIP/Postal Code
02474
Country
United States
Facility Name
Lahey Clinic, Inc.
City
Burlington
State/Province
Massachusetts
ZIP/Postal Code
01805
Country
United States
Facility Name
Lahey Clinic Northshore
City
Peabody
State/Province
Massachusetts
ZIP/Postal Code
01960
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
17061223
Citation
Kaderli B, Avci R. Comparison of topical and subconjunctival anesthesia in intravitreal injection administrations. Eur J Ophthalmol. 2006 Sep-Oct;16(5):718-21. doi: 10.1177/112067210601600509.
Results Reference
background
PubMed Identifier
18306942
Citation
Landry DA. Topical anesthetic pledgett system (TAPS) for intravitreal injection preparation. Insight. 2007 Oct-Dec;32(4):20.
Results Reference
background

Learn more about this trial

Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection

We'll reach out to this number within 24 hrs